Cargando…
Cerebral Infarction as a Rare Adverse Event of Immune Checkpoint Inhibitors in Patients With Head and Neck Squamous Cell Carcinoma: A Case Series
Immune checkpoint inhibitors (ICIs) are a novel treatment option for treating head and neck squamous cell carcinoma (HNSCC). Among the immune-related adverse effects, cerebral infarction (CI) is a rare but fatal complication, and it has been reported in various cancers, except HNSCC. Herein, we desc...
Autores principales: | Inoue, Takahiro, Kumai, Takumi, Ohara, Kenzo, Takahara, Miki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10658212/ https://www.ncbi.nlm.nih.gov/pubmed/38021593 http://dx.doi.org/10.7759/cureus.47406 |
Ejemplares similares
-
An Otogenic Variant of Lemierre's Syndrome Caused by Trueperella bernardiae: A Case Report and Literature Review
por: Kumai, Takumi, et al.
Publicado: (2023) -
IL-2 complex recovers steroid-induced inhibition in immunochemotherapy for head and neck cancer
por: Kono, Michihisa, et al.
Publicado: (2022) -
Immunomodulation via FGFR inhibition augments FGFR1 targeting T-cell based antitumor immunotherapy for head and neck squamous cell carcinoma
por: Kono, Michihisa, et al.
Publicado: (2022) -
Expression of placenta-specific 1 and its potential for eliciting anti-tumor helper T-cell responses in head and neck squamous cell carcinoma
por: Hayashi, Ryusuke, et al.
Publicado: (2020) -
Treatment outcomes of alternating chemoradiotherapy for nasopharyngeal carcinoma: a single-center safety and efficacy study
por: Ohara, Kenzo, et al.
Publicado: (2022)